Transdermal delivery: Product and patent update

Recent Patents on Drug Delivery and Formulation

Volumn 7, Issue 3, 2013, Pages 184-205

  Gupta, Himanshu ^a   Babu, R J ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Clinical trials; Iontophoresis; Microneedle; Patents transdermal patch

Indexed keywords

ADRENALIN PLUS LIDOCAINE; BUPRENORPHINE; CLADRIBINE; CLONIDINE; DEXAMETHASONE; DOT MATRIX; ENTINOSTAT; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FENTANYL; GLYCERYL TRINITRATE; GRANISETRON; INFLUENZA VACCINE; LIDOCAINE; LIDOCAINE PLUS TETRACAINE; METHYLPHENIDATE; NICOTINE; OXYBUTYNIN; PANOBINOSTAT; PIROXICAM; PLACEBO; RIVASTIGMINE; ROTIGOTINE; SCOPOLAMINE; SELEGILINE; TESTOSTERONE; TULOBUTEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANDROGEN DEFICIENCY; ANGINA PECTORIS; ANXIETY; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; CHRONIC PAIN; CONSTIPATION; DEMENTIA; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DROWSINESS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPOGONADISM; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR DEPRESSION; MALAISE; MENOPAUSAL SYNDROME; MICRONEEDLE; MOTION SICKNESS; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OVERACTIVE BLADDER; PARKINSON DISEASE; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEXUAL DYSFUNCTION; SHIVERING; SIDE EFFECT; SKIN ABRASION; SKIN ALLERGY; SKIN REDNESS; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; TRANSDERMAL PATCH;

EID: 84888994942     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221130703131128121747     Document Type: Review

References (111)

1. Guy RH. Transdermal science and technology-an update. Drug DelivSyst 2007; 22(4): 8.
2. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008; 26(11): 1261-8.
3. [30 Jan 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=794aa355-66de-41b8-aedff2c40f6bc664.
4. Mundin GESK, Bailey P. Pharmacokinetics of transdermal buprenorphine compared with sublingual buprenorphine in healthy volunteers. Royal College of General Practitioners Annual Primary Care Conference; 2011 Oct 20-22; Liverpool.
5. Plosker GL. Buprenorphine 5, 10 and 20 mug/h transdermal patch: A review of its use in the management of chronic non-malignant pain. Drugs 2011; 71(18): 2491-509. Epub 2011/12/07.
6. Clonidine. [30 Jan 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=f4ac82b0-d0fb-4720-a277-5b2b8013cb3f.
7. Langley MS, Heel RC. Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1988; 35(2): 123-42.
8. Estradiol. [30 Jan 13]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=83b78f99-df2e-46c5-b308-03bac56a8c8f.
9. Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs. 1990; 40(4): 561-82.
10. Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm? setid=2dcdd1c3-6728-45fb-97aa-de21f1f5ccad.
11. Climara. Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=1e9702c4-f2d7-4ea8-b6e8-7dca31671864.
12. Climara. [cited 2013 24 May]; Available from: http://www. medsafe. govt. nz/profs/datasheet/c/Climaratransderm. pdf.
13. Climara Pharmacokinetics. [cited 2013 24 May]; Available from: http://www. druglib. com/druginfo/climara/description_pharmacology/.
14. Climara-Newzealand Data sheet. [cited 2013 24 May]; Available from: http://www. medsafe. govt. nz/profs/datasheet/c/Climaratran sderm. pdf.
15. Climara Pro. [cited 2013 30 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=184d3092-7fc6-4375-816b-1ab06bb99cfd.
16. Shulman LP. 17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman. Exp Opin Pharmacotherap 2004; 5(12): 2559-66.
17. Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, doubleblind, randomized, controlled trials. Menopause 2002; 9(3): 195-207. Epub 2002/04/26.
18. CombiPatch. [cited 2013 30 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=8fab92c2-5827-4c62-a4f6-4f2547dc5233.
19. Adler G, Young D, Galant R, Quinn L, Witchger MS, Maki KC. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecologic Obstet Investigat 2005; 59(4): 212-9.
20. Orthoevra. [cited 2013 26 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=f8e8a69e-a018-469a-af56-e20f61fe4e06.
21. Abrams LS, Skee DM, Natarajan J, Wong FA, Anderson GD. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Brit J Clin Pharmacol 2002; 53(2): 141-6.
22. Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertility Sterility 2002; 77(2 Suppl 2): S3-12.
23. Fentanyl TDS. Available from: http://dailymed. nlm. nih. gov/dailymed/drugInfo. cfm?id=72227.
24. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989; 70(6): 928-34.
25. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: An updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289-307.
26. Durogesic (Fentanyl transdermal system) full prescribing information (US). Janssen Pharmaceutica; 2001.
27. Ionsys. Available from: http://www. rxlist. com/ionsys-drug. htm.
28. Sancuso. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=ba44e7d8-0c71-4eb9-a951-3d91038293c5.
29. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapyinduced nausea and vomiting. Journal of oncology pharmacy practice: Official publication of the International Society of Oncology Pharmacy Practitioners 2009; 15(4): 223-31.
30. Howell J CG, Yellowlees A, editor. Efficacy, safety and tolerability of a transdermal granisetron patch for prevention of single-dose chemotherapy-induced nausea and vomiting: Phase II trial results Hematology/Oncology Pharmacy Association Annual Meeting 2009; Jun 17-20.
31. Duggan ST, Curran MP. Transdermal granisetron. Drugs 2009; 69(18): 2597-605.
32. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000; 59(2): 245-9; discussion 50-1.
33. Lidoderm package insert. In: (PA) CF, editor. Endo Pharmaceuticals Inc. 1999.
34. Synera [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=b3eee508-8bf3-4bd3-9a71-47ee6ea 87f95.
35. Curry SEFJ. Use of the Synera patch for local anesthesia before vascular access procedures: A randomized, double-blind, placebocontrolled study. Pain Med. 2007; 8(6): 5.
36. Daytrana. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=2c312c31-3198-4775-91ab-294e0b4b9e7f.
37. th Annual US Psychiatric and Mental Health Congress; 2005 Nov 7-10; Las Vegas, NV.
38. DaytranaTM (methylphenidate transdermal system) [database on the Internet]. Shire Pharmaceuticals Ireland Limited. Available from: www. daytrana. com.
39. Anderson VR, Scott LJ. Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children. Drugs 2006; 66(8): 1117-26.
40. Palmer KJ, Buckley MM, Faulds D. Transdermal Nicotine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs 1992; 44(3): 498-529.
41. Nicotine CQ. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=93b2d1b9-83c1-40b5-b6af-90c38c8d6cef.
42. Benowitz NL, Jacob P, 3rd, Fong I, Gupta S. Nicotine metabolic profile in man: Comparison of cigarette smoking and transdermal nicotine. J Pharmacol Experiment Therapeut 1994; 268(1): 296-303.
43. Fant RV, Henningfield JE, Shiffman S, Strahs KR, Reitberg DP. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 2000; 67(3): 479-82.
44. Transderm Nitro. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=DB8A99DBFC48-437B-B429-DD755E14EF54.
45. Todd PA, Goa KL, Langtry HD. Transdermal nitroglycerin (glyceryltrinitrate). A review of its pharmacology and therapeutic use. Drugs 1990; 40(6): 880-902.
46. Minitran patch. [cited 2013 24 May]; Available from: http://www. medsafe. govt. nz/profs/datasheet/m/Minitranpatch. htm.
47. Oxytrol. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=a162fd5b-b2ab-4d45-8861-71b60b92acb4.
48. Zobrist RH, Quan D, Thomas HM, Stanworth S, Sanders SW. Pharmacokinetics and metabolism of transdermal oxybutynin: In vitro and in vivo performance of a novel delivery system. Pharmaceutical research 2003; 20(1): 103-9.
49. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clinic proceedings 2003; 78(6): 696-702.
50. Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Design, Develop Therap 2009; 2: 245-54.
51. Exelon. [cited 2013 30 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0.
52. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71(9): 1209-31.
53. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Exp Opin Pharmacotherap 2009; 10(4): 677-91.
54. NeuPro. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=939e28c5-f3a9-42c0-9a2d-8d471d82a6e0.
55. Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29(3): 189-207.
56. Scopolamine. [cited 2013]; Available from: http://dailymed. nlm. nih. gov/dailymed/drugInfo. cfm?id=76699.
57. Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (emsam): A therapeutic option for the treatment of major depressive disorder. P & T: A peer-reviewed journal for formulary management 2008; 33(4): 212-46.
58. Ziemniak JA, Kemper EM, Goodhear M, Azzaro AJ. Pharmacokinetcs of selegiline administered via transdermal patch, single oral dose, or intravenous infusion [poster]. New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting; 2001 29 May; Pheonix, AZ.
59. Emsam. [cited 2013 30 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=b891bd9f-fdb8-4862-89c5-ecdd700398a3.
60. Frampton JE, Plosker GL. Selegiline transdermal system: In the treatment of major depressive disorder Drugs. 2007; 67(2): 257-65.
61. Mazer NAHW. Moellmer Enhanced transdermal delivery of testosterone: A new physiological approach for androgen replacement in hypogonadal men. J Control Release 1992; 19(1-3).
62. Testosterone. [cited 2013 29 Jan]; Available from: http://dailymed. nlm. nih. gov/dailymed/lookup. cfm?setid=ac40e05b-6e67-4ff9-a0e8-2e897e71b282.
63. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site--a clinical research center study. J Clin Endocrinol Metabolism 1996; 81(5): 1832-40.
64. Brocks DR, Meikle AW, Boike SC, Mazer NA, Zariffa N, Audet PR, et al. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: Influence of dose. J Clinic Pharmacol 1996; 36(8): 732-9.
65. Prescribing information: Androderm® testosterone transdermal controlled-delivery for once-daily application [database on the Internet]. Available from: http://www. androderm. com/prescribe. htm1#-prescribe.
66. McClellan KJ, Goa KL. Transdermal testosterone. Drugs 1998; 55(2): 253-8.
67. Product information: Fluzone intradermal [FDA database] available from: http://www. fda. gov/downloads/biologicsbloodvaccines/./ucm1954 79. pdf Date accessed 27 July 2013.
68. Caldwell, L., Shirai, S. Extended-release β-agonist/anticholinergic transdermal patches for treatment of pulmonary disorders. WO2012103016A2 (2012).
69. Therkleson, T. C. Transdermal patch comprising Zingiberofficinale rhizome for the treatment of arthritic conditions. WO2012026829A1 (2012).
70. Wang, C., Sheu, E. Y., Vuong, N. Piroxicam matrix transdermal patches for treatment of acute and chronic pain and inflammation. WO2011150239A2 (2011).
71. Epner, E. M., Vaughan, L. M. Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor. US20120310183A1 (2012).
72. Feldkamp, J. R., Koenig, D. W., Wenzel, S. W., Joseph, W. Transdermal delivery of oleocanthal for relief of inflammation. US7879344B2 (2011).
73. Qiu, Y., Kuo, J. S., Kuo, G. P., Chiang, C.-C., Chen, P. R. Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome. WO2011005853A2 (2011).
74. Breitenbach, A., Klaffenbach, P., Lehrke, I., Vollmer, U. Transdermal system for the delivery of sufentanil and its analogs for pain treatment. US20090130190A1 (2009).
75. Anderson, C. R., Morris, R. L., Cohen, R., Fowler, W. V. Integrated iontophoresis transdermal systems for corticosteroid delivery. patent US20090062720A1 (2009).
76. Zhang, J., Warner, K. S. Transdermal drug delivery systems for delivering anti-inflammatory drugs. patent WO2008150995A2. (2008).
77. Choi, Y.-G., Ki, H.-M., Ah, Y.-C., Kim, J.-J. Transdermal patch preparations containing hydrophobic non-steroidal antiinflammatory drugs, employing an acrylic adhesive system. WO2008007926A1 (2008).
78. Breitenbach, A., Klaffenbach, P., Lehrke, I., Vollmer, U. Transdermal delivery system comprising sufentanil and its analogs for pain treatment. WO2007121949A1 (2007).
79. Smith, D. J., Badria, M. J., Williams, O., Weimann, L. J. Multicompartment transdermal pain control device. US20070248657A1 (2007).
80. Ough, Y. D. Soap scent patch and treatment for muscle spasm and pain. US20060182819A1 (2006).
81. Wang, Y., Li, W., Zhou, X. Antiviral transdermal patch and method for producing the same. US20120089104A1 (2012).
82. Wu, C.-J., Cheng, J.-Y., Huang, H.-N. Lipoplex-patch based DNA vaccine against viral infections. US20110182976A1 (2011).
83. Jacobsen, J. P. R., Caron, M. G. Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies. WO2012054815A1 (2012).
84. Chi, S. C. Transdermal patch comprising paroxetine. WO2007011125A1 (2007).
85. Franklin, R. Transdermal delivery of meptazinol providing analgesic relief. WO2007075883A2 (2007).
86. Venkatraman, S. S., Li, S., Gale, R. M., Stepic, J., Van, O. W. W. Transdermal administration of fentanyl and analogs thereof. US20050208117A1 (2005).
87. Keith, A. D. Aspirin transdermal patch. WO2005084255A2 (2005).
88. Patel, K. J., Borsadia, S. Transdermal method and patch for emesis comprising a 5-HT3 receptor antagonist. US20070087044A1 (2007).
89. Lebo, D. B., Lee, J., Ryoo, J. P., Toigo, O. J., III, Cupo, F. Transdermal antiemesis delivery system comprising a selective 5-HT3 receptor antagonist. WO2006028863A1 (2006).
90. Krivonos, S. Crystalline rotigotine base and preparation process therefor. WO2008146284A2 (2008).
91. Braun, M., Cawello, W., Foster, E. B., Lauterbach, T., Wolff, H.-M. Transdermal therapeutic system for Parkinson's disease. WO2006039532A2 (2006).
92. Yang, K.-H., Yang, C.-S., Lin, H.-Y. Donepezil transdermal patch comprising a polymer-based pressure-sensitive adhesive. WO2012097197A1 (2012).
93. Chowdhury, D. F. H. Multi-layered transdermal patch comprising a polymer adhesive and a penetration enhancer. GB2485637A (2012).
94. Colas, A., Schalau, G. K., Thomas, X. Multi-layer transdermal patch. WO2011022199A2 (2011).
95. Clarke, D. E. Nicotine combination with antidepressant for the treatment of ulcerative colitis. US20050234024A1 (2005).
96. Lindell, E. A. K., Nicklasson, P. F., Thyresson, M. K. Means for transdermal administration of nicotine. WO2005089728A2 (2005).
97. Stinchcomb, A. L., Li, G., Banks, S. L., Howard, J. L., Golinski, M. J. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists. WO2011123866A1 (2011).
98. Weimann, L. J. Transdermal patches comprising an adhesive adhesive and naltrexone. WO2009106831A2 (2009).
99. Royds, R. B. Transdermal patch comprising opioid agonist. US20080008747A1 (2008).
100. Jain, U., Venkateshwaran, S., Ebert, C. Transdermal delivery compositions for improved stability of steroids. EP2305195A1 (2011).
101. Murray, J. R., Kamiyama, F., Wuelfert, E. Transdermal steroid formulation for treatment of osteoporosis. WO2005105104A1 (2005).
102. Sexton, F. A. Transdermal patch with plural on-board energy storage devices. US20120116308A1 (2012).
103. Kraft, D. L. System and methods for the production of personalized drug products. WO2012021899A2 (2012).
104. Imran, M., Andersen, D. P., Malhotra, V., Mangogna, G. A. Methods and architecture for power optimization of iontophoretic transdermal drug delivery. WO2011100376A2 (2011).
105. Anderson, C. R., Morris, R. L., Cohen, R. Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisions. US7904146B2 (2011).
106. Baird, R. A., Barnett, B. L., Beste, R. D. Process for the continuous manufacture of a polyisobutylene based transdermal patch. WO2011011318A1 (2011).
107. Bommannan, D. B. Transdermal patch device for delivery of antidote. US20100286600A1 (2010).
108. Lisziewicz, J. Topical or transdermal delivery kit for cosmetics, drugs, nanoparticles and vaccines. WO2010097773A1 (2010).
109. Borland, R. E. Jr. Transdermal thiamine insect repellant. US7754237B1 (2010).
110. Schmitz, C., Sameti, M., Koch, A., Horstmann, M. Composition for iontophoretic transdermal delivery of cationic active agents. WO2009153019A1 (2009).
111. Aronowitz, J. L., Mitchen, J. R., Weiss, J., Weitman, I. Noninvasive transdermal systems for detecting an analyte in a biological fluid and methods. US7577469B1 (2009).